A Phase III, Double-Blind, Randomized, Placebo-Controlled, Multi-Country and Multi-Center Study to Assess the Efficacy and Safety of Two Doses of GSK Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine in Healthy Infants
Phase of Trial: Phase III
Latest Information Update: 03 Jun 2015
At a glance
- Drugs RIX 4414 (Primary)
- Indications Gastroenteritis; Rotavirus infections
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline
- 03 Oct 2011 Additional trial investigator identified as reported by ClinicalTrials.gov (NCT00197210).
- 23 Sep 2011 Actual end date of the extension trial (NCT00329745) is Jul 2008.
- 23 Sep 2011 Status of the extension trial (NCT00329745) is completed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History